Markets:

Overview

News

Currencies

International

Treasuries

Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

18.88 +0.29 (+1.56%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Sarepta Therapeutics, Inc. - Common Stock

< Previous 1 2

...

12 13 14 15 16 17 18 19 20

...

22 23 Next >

3 Revolutionary Stocks I'd Buy Right Now Without Hesitation ↗

August 22, 2023

Helping save and improve patients' lives in novel ways can be a lucrative activity.

Via The Motley Fool

Over $25M Bet On This Healthcare Stock? Check Out These 3 Stocks Insiders Are Buying ↗

August 15, 2023

Although U.S. stocks closed mostly higher on Monday, there were a few notable insider trades.

Via Benzinga

$3M Bet On Tidewater? Check Out These 4 Stocks Insiders Are Buying ↗

August 14, 2023

Although U.S. stocks closed mixed on Friday, there were a few notable insider trades.

Via Benzinga

Analyst Ratings for Sarepta Therapeutics ↗

August 03, 2023

Via Benzinga

Sarepta Therapeutics (SRPT) Q2 2023 Earnings Call Transcript ↗

August 02, 2023

SRPT earnings call for the period ending June 30, 2023.

Via The Motley Fool

Earnings Preview: Sarepta Therapeutics ↗

August 01, 2023

Via Benzinga

2 Biotech Growth Stocks I'd Buy Right Now ↗

July 27, 2023

Both drugmakers seem to have a bright future ahead.

Via The Motley Fool

Where Sarepta Therapeutics Stands With Analysts ↗

July 14, 2023

Via Benzinga

What 25 Analyst Ratings Have To Say About Sarepta Therapeutics ↗

June 23, 2023

Via Benzinga

Sarepta Wins FDA Approval For Highly Anticipated Gene Therapy ↗

June 22, 2023

Sarepta will sell the Duchenne muscular dystrophy gene therapy under the brand name Elevidys.

Via Investor's Business Daily

3 Biotech Stocks to Sell Before They Damage Your Portfolio ↗

July 12, 2023

With the Street generally bearish towards the biotech sector, investors need to identify biotech stocks to avoid at this point.

Via InvestorPlace

Sarepta Therapeutics' Stock Is Down 14% in 1 Month, So Why Does Wall Street Expect It to Rise 65%? ↗

June 30, 2023

While its gene therapy for Duchenne muscular dystrophy has been conditionally approved, it'll take a while to prove its merit.

Via The Motley Fool

Why CarMax Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗

June 23, 2023

Gainers Kidpik Corp. (NASDAQ: PIK) shares jumped 122% to $1.29. Kidpik teamed up with Disney to celebrate the release of Disney+ original movie 'World's Best'.

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For June 23, 2023 ↗

June 23, 2023

Via Benzinga

24 Analysts Have This to Say About Sarepta Therapeutics ↗

June 06, 2023

Via Benzinga

Canopy Growth, Avadel Pharmaceuticals And Other Big Stocks Moving Lower On Friday ↗

June 23, 2023

U.S. stocks traded lower, with the Nasdaq Composite dropping around 100 points on Friday. Here are some big stocks recording losses in today’s session. GSR II Meteora Acquisition Corp. (NASDAQ: GSRM)...

Via Benzinga

Sarepta Therapeutics' Therapy Becomes First To Score FDA Nod For Duchenne Muscular Dystrophy Gene Therapy ↗

June 22, 2023

The FDA has granted accelerated approval to closely watched Sarepta Therapeutics Inc's (NASDAQ: SRPT) gene therapy, Elevidys, for Duchenne muscular dystrophy (DMD) in ambulatory pediatric patients aged...

Via Benzinga

RegenXbio's Potential Blockbuster: Analyst is Bullish On Stock Citing Potential Gains From AAV Gene Therapies Resurgence ↗

June 20, 2023

Baird has initiated coverage on RegenXbio Inc (NASDAQ: RGNX) with an Outperform rating and a

Via Benzinga

3 Small-Cap Drug Stocks to Watch as Their Clinical Trials End Soon ↗

June 12, 2023

These three small cap drug companies could become gold or lead depending on the outcomes of their clinical trials.

Via InvestorPlace

How Biohaven Is Coming 'Out Of Stealth Mode' — And Bullishly Extending A 4-Day Run ↗

June 01, 2023

Shares surged into and out of the company's R&D Day, which included a surprise.

Via Investor's Business Daily

Is Sarepta Therapeutics' Gene Therapy in Danger of Not Obtaining FDA Approval? ↗

June 01, 2023

The stock has now given back all of its 2023 gains as investors' fears mount.

Via The Motley Fool

Why Shares of Sarepta Therapeutics Are Dropping Wednesday ↗

May 24, 2023

The FDA told the company that a review of a new therapy will take nearly a month longer.

Via The Motley Fool

Why America's Car-Mart Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗

May 24, 2023

Gainers Minerva Surgical, Inc. (NASDAQ: UTRS) shares jumped 209.1% to $0.5622 after the United States Patent and Trademark Office granted the company a patent for certain medical systems and methods.

Via Benzinga

2 Under-the-Radar Biotech Stocks to Buy in 2023 ↗

May 24, 2023

Companies that don't make a lot of noise can still make you a lot of money.

Via The Motley Fool

Sarepta Therapeutics Dives On An Unexpected Hold-Up For Its Gene Therapy ↗

May 24, 2023

The company is working to treat Duchenne muscular dystrophy, a muscle-wasting disease.

Via Investor's Business Daily

Why These 3 Nasdaq Stocks Buckled Today ↗

May 16, 2023

The FTC's decision to sue to block a high-profile merger is weighing on biotech valuations today.

Via The Motley Fool

12 Health Care Stocks Moving In Monday's Intraday Session ↗

May 15, 2023

Via Benzinga

Why Is Sarepta (SRPT) Stock Up 29% Today? ↗

May 15, 2023

Sarepta (SRPT) stock is on the move Monday as investors react to FDA advisors voting on its gene therapy for Duchenne muscular dystrophy.

Via InvestorPlace

Sarepta Therapeutic Shares Surge 25% Following Favorable Gene Therapy Vote; Analyst Anticipates Huge Earnings Swing In 2024 ↗

May 15, 2023

Sarepta Therapeutics Inc (NASDAQ: SRPT) shares jumped nearly 24% on Monday morning after a panel of experts voted last Friday in favor of the company's DMD gene therapy for accelerated approval in...

Via Benzinga

Why Venus Concept Shares Are Trading Lower By Over 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

May 15, 2023

Gainers NeoGames S.A. (NASDAQ: NGMS) shares climbed 113.3% to $27.38 as the company agreed to be acquired by Aristocrat Leisure Limited for $29.50 per share in cash.

Via Benzinga

< Previous 1 2

...

12 13 14 15 16 17 18 19 20

...

22 23 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

Headline News about Sarepta Therapeutics, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today